CDX-014
- Generic Name
- CDX-014
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Phase 1
Terminated
- Conditions
- Kidney NeoplasmsRenal Cell Carcinoma (RCC)Clear-cell Renal Cell CarcinomaPapillary Renal Cell CarcinomaMetastatic Renal Cell CarcinomaOvarian Clear Cell Carcinoma
- Interventions
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT02837991
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath